ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $54.08 and traded as low as $52.40. ProShares Ultra Nasdaq Biotechnology shares last traded at $55.13, with a volume of 14,819 shares.
ProShares Ultra Nasdaq Biotechnology Price Performance
The firm's 50 day moving average price is $54.08 and its two-hundred day moving average price is $60.75.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The firm also recently announced a dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 23rd were issued a $0.3964 dividend. The ex-dividend date of this dividend was Monday, December 23rd. This is a positive change from ProShares Ultra Nasdaq Biotechnology's previous dividend of $0.15.
Institutional Inflows and Outflows
An institutional investor recently raised its position in ProShares Ultra Nasdaq Biotechnology stock. Jane Street Group LLC raised its stake in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Free Report) by 8.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,803 shares of the exchange traded fund's stock after acquiring an additional 374 shares during the quarter. Jane Street Group LLC owned approximately 0.35% of ProShares Ultra Nasdaq Biotechnology worth $306,000 as of its most recent filing with the Securities & Exchange Commission.
About ProShares Ultra Nasdaq Biotechnology
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Featured Stories
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
